today announced the presentation of preclinical data on CS2009, a leading asset from the Company’s Pipeline 2.0, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC
SITC 2024 Annual Review Meeting Briefing On February 15, 2025, SITC held 2024 annual review meeting. Chairman of the Board of Directors Yang Xianxiang, CEO Xue Mingyuan, heads of each company and above attended the meeting, and all the staff of SITC's subsidiaries participated in the meeting...
PERLA试验结果显示:与帕博利珠单抗相比,Dostarlimab联合化疗在晚期NSCLC中显示出更好的总生存,中位OS为20.2个月 vs 15.9个月。 试验的主要终点是客观缓解率,次要终点包括总生存、无进展生存和安全性。 PERLA试验的OS结果显示,Dostarlimab联合...
SITC 2024 Annual Review Meeting Briefing On February 15, 2025, SITC held 2024 annual review meeting. Chairman of the Board of Directors Yang Xianxiang, CEO Xue Mingyuan, heads of each company and above attended the meeting, and all the staff of SITC's subsidiaries participated in the meeting...
“SITC”) 2024 Annual Meeting. Theposter presentationincludes updated translational data highlighting the relationship between vaccine immunogenicity and DFS. The AMPLIFY-7P study is evaluating ELI-002 in patients with mKRAS-driven solid tumors following standard locoregional treatment and...
November 7 -2024, - At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting...
2022年癌症免疫治疗学会 (SITC)第37届年会和会前计划 (SITC 2022) 将于 2022 年 11 月 9 日至 13 日在波士顿的波士顿会展中心举行。37th Annual Meeting & Pre-Conference Programs (SITC 2022)作为专注于癌症免疫治疗的最大会议,年会和会前计划为来自学术界、监管机构和政府机构的国际领导者以及行业代表提供了...
SITC 202417+ SOCIETY FOR IMMUNOTHERAPY OF CANCER, INC. Designed for iPad Free Screenshots iPad iPhone Description 39th Annual Meeting & Pre-Conference Programs Nov. 6–10, 2024 Make your mark at the largest cancer immunotherapy conference and exhibit at SITC’s 39th Annual Meeting, hosted by the...
SITC 202417+ SOCIETY FOR IMMUNOTHERAPY OF CANCER, INC. Designed for iPad Free Screenshots iPad iPhone Description 39th Annual Meeting & Pre-Conference Programs Nov. 6–10, 2024 Make your mark at the largest cancer immunotherapy conference and exhibit at SITC’s 39th Annual Meeting, hosted by the...
6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting,...